PFEPfizerRunning, no new patients
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Breast Cancer · Head and Neck Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 35 (final count)
- Started
- Jul 7, 2022
- Main results expected
- Dec 31, 2029
- Fully finished
- Dec 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number/Percentage of Participants with Treatment-Emergent Adverse Events (AEs) Leading to Permanent Discontinuation of Study Treatment and Serious Adverse Events (SAEs)
Measured over: Baseline up to 28 days after last dose of study intervention
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05226871 · record last updated 2026-09-09 · checked 2026-11-09 15:36 UTC